SCHEMBL12090969

SCHEMBL12090969

Cc1cccc(-c2c(C(OC(C)(C)C)C(=O)O)c(C)nc3cc(-c4ccccc4)nn23)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1I2 O75469 1/20 0.62
▸ NPC1 O15118 5/20 0.46
▸ RAB9A P51151 5/20 0.46
▸ KDM4E B2RXH2 4/20 0.46
▸ MAPT P10636 1/20 0.45
▸ HPGD P15428 4/20 0.44
▸ ALDH1A1 P00352 3/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ NFKB1 P19838 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ NFKB2 Q00653 1/20 0.44
▸ RELA Q04206 1/20 0.44
▸ KMT2A Q03164 2/20 0.40
▸ TAAR1 Q96RJ0 1/20 0.40
▸ DPP4 P27487 1/20 0.40
▸ DPP8 Q6V1X1 1/20 0.40
▸ DPP9 Q86TI2 1/20 0.40
▸ PSIP1 O75475 1/20 0.40
▸ GAA P10253 2/20 0.39
▸ HCRTR1 O43613 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12091025 0.93 NR1I2 (0.66) NR1I2NPC1RAB9AKDM4EMAPT
SCHEMBL10174452 0.91 NR1I2 (0.62) NR1I2NPC1RAB9AKDM4EMAPT
SCHEMBL10174791 0.90 NR1I2 (0.60) NR1I2NPC1RAB9AKDM4EMAPT
SCHEMBL15479182 0.90 NR1I2 (0.62) NR1I2NPC1RAB9AKDM4EMAPT
SCHEMBL12090957 0.90 NR1I2 (0.59) NR1I2KDM4EMAPTHPGDALDH1A1
SCHEMBL461476 0.89 NR1I2 (0.63) NR1I2NPC1RAB9AKDM4EMAPT
SCHEMBL12090950 0.89 NR1I2 (0.61) NR1I2NPC1RAB9AKDM4EMAPT
SCHEMBL10174794 0.89 NR1I2 (0.60) NR1I2NPC1RAB9AKDM4EMAPT
SCHEMBL470358 0.89 NR1I2 (0.64) NR1I2NPC1RAB9AKDM4EMAPT
SCHEMBL470401 0.88 NR1I2 (0.62) NR1I2NPC1RAB9AKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 — — US disclosed
US-8633200-B2 Inhibitors of human immunodeficiency virus replication BRISTOL-MYERS SQUIBB COMPANY (US) 2014-01-21 — — US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 — — US disclosed
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication BRISTOL-MYERS SQUIBB COMPANY 2012-09-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225888-A1 Inhibitors of Human Immunodeficiency Virus Replication EIF2AK2, RTF2, MAVS NR1I2 3085/4885NPC1 434/4885RAB9A 1173/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback